| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| S Horschitz, R Hummerich, T Lau, M Rietschel, P Schlos. A dopamine transporter mutation associated with bipolar affective disorder causes inhibition of transporter cell surface expression. Molecular psychiatry. vol 10. issue 12. 2006-03-01. PMID:16103889. |
the dopamine transporter (dat) plays a crucial role in dopaminergic neurotransmission as it clears the extracellular space of dopamine (da) and thus controls the concentration of active neurotransmitter. |
2006-03-01 |
2023-08-12 |
human |
| Kyoji Ohyama, Pamela Ellis, Shioko Kimura, Marysia Placze. Directed differentiation of neural cells to hypothalamic dopaminergic neurons. Development (Cambridge, England). vol 132. issue 23. 2006-02-14. PMID:16284116. |
shh acts early to specify dopaminergic neurotransmitter phenotype. |
2006-02-14 |
2023-08-12 |
mouse |
| William Slikker, Z Alex Xu, Edward D Levin, Theodore A Slotki. Mode of action: disruption of brain cell replication, second messenger, and neurotransmitter systems during development leading to cognitive dysfunction--developmental neurotoxicity of nicotine. Critical reviews in toxicology. vol 35. issue 8-9. 2006-02-08. PMID:16417037. |
other events include an initial increase followed by a decrease in adenyl cyclase activity, as well as effects on the noradrenergic, dopaminergic, and serotonergic neurotransmitter systems. |
2006-02-08 |
2023-08-12 |
human |
| Thomas J H Chen, Kenneth Blum, Daniel Mathews, Larry Fisher, Nancy Schnautz, Eric R Braverman, John Schoolfield, Bernard W Downs, David E Coming. Are dopaminergic genes involved in a predisposition to pathological aggression? Hypothesizing the importance of "super normal controls" in psychiatricgenetic research of complex behavioral disorders. Medical hypotheses. vol 65. issue 4. 2006-02-06. PMID:15964153. |
while a number of neurotransmitter systems must be involved, due to polygenic inheritance, one major pathway should involve the dopaminergic system. |
2006-02-06 |
2023-08-12 |
Not clear |
| Matthew J LaVoie, Beth L Ostaszewski, Andreas Weihofen, Michael G Schlossmacher, Dennis J Selko. Dopamine covalently modifies and functionally inactivates parkin. Nature medicine. vol 11. issue 11. 2005-12-28. PMID:16227987. |
here we report that the neurotransmitter dopamine covalently modifies parkin in living dopaminergic cells, a process that increases parkin insolubility and inactivates its e3 ubiquitin ligase function. |
2005-12-28 |
2023-08-12 |
human |
| Filip Scheperjans, Nicola Palomero-Gallagher, Christian Grefkes, Axel Schleicher, Karl Zille. Transmitter receptors reveal segregation of cortical areas in the human superior parietal cortex: relations to visual and somatosensory regions. NeuroImage. vol 28. issue 2. 2005-12-22. PMID:16054841. |
regional distributions of ligand binding sites of 12 different neurotransmitter receptors (glutamatergic: ampa, kainate, nmda; gabaergic: gaba(a), gaba(b); cholinergic: muscarinic m2, nicotinic; adrenergic: alpha1, alpha2; serotonergic: 5-ht1a, 5-ht2; dopaminergic: d1) were studied in human postmortem brains by means of quantitative receptor autoradiography. |
2005-12-22 |
2023-08-12 |
human |
| Shigeyoshi Fuziwara, Ayako Suzuki, Kaori Inoue, Mitsuhiro Dend. Dopamine D2-like receptor agonists accelerate barrier repair and inhibit the epidermal hyperplasia induced by barrier disruption. The Journal of investigative dermatology. vol 125. issue 4. 2005-11-03. PMID:16185279. |
two families of g protein-coupled receptors of the neurotransmitter dopamine, i.e., dopamine 1-like family (d1-like receptor) and dopamine 2-like family (d2-like receptor), show dopaminergic activity in nerve cells. |
2005-11-03 |
2023-08-12 |
Not clear |
| Spiridon Papapetropoulos, D C Mas. Psychotic symptoms in Parkinson's disease. From description to etiology. Journal of neurology. vol 252. issue 7. 2005-10-27. PMID:15999234. |
although the precise pathoetiologic mechanisms remain unknown, we review evidence that links ventral dopaminergic pathway dysfunction (overactivity) together with the involvement of other neurotransmitter system imbalances as likely contributors. |
2005-10-27 |
2023-08-12 |
Not clear |
| Spiridon Papapetropoulos, D C Mas. Psychotic symptoms in Parkinson's disease. From description to etiology. Journal of neurology. vol 252. issue 7. 2005-10-27. PMID:15999234. |
the clinical importance of the proposed mechanism is that successful management of psychotic symptoms in pd may rely on a multitarget approach to restore neurotransmitter imbalances rather than focusing exclusively on the dopaminergic dysfunction. |
2005-10-27 |
2023-08-12 |
Not clear |
| Teresa M du Bois, Chao Deng, Xu-Feng Huan. Membrane phospholipid composition, alterations in neurotransmitter systems and schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 29. issue 6. 2005-10-27. PMID:16005134. |
this review addresses the relationship between modifications in membrane phospholipid composition (mpc) and alterations in dopaminergic, serotonergic and cholinergic neurotransmitter systems in schizophrenia. |
2005-10-27 |
2023-08-12 |
rat |
| S Rossi, S Singer, E Shearman, H Sershen, A Lajth. The effects of cholinergic and dopaminergic antagonists on nicotine-induced cerebral neurotransmitter changes. Neurochemical research. vol 30. issue 4. 2005-08-24. PMID:16076024. |
the effects of cholinergic and dopaminergic antagonists on nicotine-induced cerebral neurotransmitter changes. |
2005-08-24 |
2023-08-12 |
rat |
| Abdurrahman Altindag, Medaim Yanik, Mehmet Asogl. The emergence of tics during escitalopram and sertraline treatment. International clinical psychopharmacology. vol 20. issue 3. 2005-08-02. PMID:15812270. |
we present a case of the emergence of tics associated with escitalopram and sertraline treatment, which might be due to an imbalance in the dopaminergic neurotransmitter system. |
2005-08-02 |
2023-08-12 |
Not clear |
| Filip Scheperjans, Christian Grefkes, Nicola Palomero-Gallagher, Axel Schleicher, Karl Zille. Subdivisions of human parietal area 5 revealed by quantitative receptor autoradiography: a parietal region between motor, somatosensory, and cingulate cortical areas. NeuroImage. vol 25. issue 3. 2005-07-29. PMID:15808998. |
we studied the regional and laminar distributions of the binding sites of 12 different neurotransmitter receptors (glutamatergic: ampa, kainate, nmda; gabaergic: gabaa, gabab; cholinergic: muscarinic m2, nicotinic; adrenergic: alpha1, alpha2; serotoninergic: 5-ht1a, 5-ht2; dopaminergic: d1) in human postmortem brains by means of quantitative receptor autoradiography, since the structural and functional aspects of human ba 5 are widely unknown, and previous observations have demonstrated characteristic differences in receptor distribution between motor and somatosensory areas. |
2005-07-29 |
2023-08-12 |
human |
| Rui D S Prediger, Daniel Fernandes, Reinaldo N Takahash. Blockade of adenosine A2A receptors reverses short-term social memory impairments in spontaneously hypertensive rats. Behavioural brain research. vol 159. issue 2. 2005-07-19. PMID:15817183. |
these cognitive deficits have been variously attributed to disrupted dopaminergic, cholinergic and adenosinergic neurotransmitter function. |
2005-07-19 |
2023-08-12 |
rat |
| A J Herrera, M Tomás-Camardiel, J L Venero, J Cano, A Machad. Inflammatory process as a determinant factor for the degeneration of substantia nigra dopaminergic neurons. Journal of neural transmission (Vienna, Austria : 1996). vol 112. issue 1. 2005-06-07. PMID:15599609. |
this single injection produced the induction of inflammatory process with the activation of microglia along with the specific degeneration of dopaminergic neurons in the sn without affecting neither other neurotransmitter systems nor other structures of the cns. |
2005-06-07 |
2023-08-12 |
Not clear |
| Stephen I Deutsch, Katrice D Long, Richard B Rosse, John Mastropaolo, Judy Elle. Hypothesized deficiency of guanine-based purines may contribute to abnormalities of neurodevelopment, neuromodulation, and neurotransmission in Lesch-Nyhan syndrome. Clinical neuropharmacology. vol 28. issue 1. 2005-05-24. PMID:15711436. |
the neurologic manifestations may result, at least in part, from a mixture of neurodevelopmental (eg, a failure to "arborize" dopaminergic synaptic terminals) and neurotransmitter (eg, disruption of gaba and glutamate receptor-mediated neurotransmission) consequences. |
2005-05-24 |
2023-08-12 |
Not clear |
| Regina Celia Cussa Kubrusly, Maria Cristina Caldas da Cunha, Ricardo Augusto de Melo Reis, Heline Soares, Ana Lúcia Marques Ventura, Eleonora Kurtenbach, Maria Cristina Fialho de Mello, Fernando Garcia de Mell. Expression of functional receptors and transmitter enzymes in cultured Muller cells. Brain research. vol 1038. issue 2. 2005-05-24. PMID:15757630. |
we developed a purified muller glia culture to investigate the expression of several neurotransmitter markers on these cells, such as dopaminergic, cholinergic, gabaergic and peptidergic receptors or enzymes, based on functional assays measuring second messenger levels or western blot for specific proteins. |
2005-05-24 |
2023-08-12 |
chicken |
| Gwyneth Zai, Paul Arnold, Eliza Burroughs, Cathy L Barr, Margaret A Richter, James L Kenned. Evidence for the gamma-amino-butyric acid type B receptor 1 (GABBR1) gene as a susceptibility factor in obsessive-compulsive disorder. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. vol 134B. issue 1. 2005-05-09. PMID:15685626. |
although historically genetic testing has focused on the serotonergic and dopaminergic systems, there is increasing evidence that the major inhibitory neurotransmitter, gamma-aminobutyric acid (gaba), may also be functionally involved. |
2005-05-09 |
2023-08-12 |
Not clear |
| Jolanta Rabe-Jabłońska, Adam Mille. [Links between pain and depression]. Psychiatria polska. vol 39. issue 1. 2005-04-21. PMID:15771150. |
presently we know at least five kinds of links between depression and pain: 1) depression appeared prior to the start of pain, 2) depression is a consequence of chronic pain and stress, 3) depressive episodes cause an increase of risk of next affective episodes in patients with chronic pain, 4) psychologic factors play an important role in the development of depressive symptoms, 5) altered balance between noradrenergic and serotonergic pathways and disregulation of other neurotransmitter systems (cholinergic, gaba-ergic, dopaminergic) and neuropeptides may cause chronic pain and depressive disorder. |
2005-04-21 |
2023-08-12 |
Not clear |
| Mehmet Sofuoglu, Thomas R Koste. Novel approaches to the treatment of cocaine addiction. CNS drugs. vol 19. issue 1. 2005-03-21. PMID:15651902. |
gaba is the main inhibitory neurotransmitter in the brain, and accumulating evidence suggests that the gaba system modulates the dopaminergic system and cocaine effects. |
2005-03-21 |
2023-08-12 |
Not clear |